OpenAI’s former exec disagrees with Amodei on most things, but backs his AI cancer view

Fidji Simo concurs with Dario Amodei on the crucial need for AI companies to demonstrate genuine medical advancements. It's essential for these enterprises to show tangible outcomes rather than relying solely on marketing strategies. Simo identifies biological data as a critical hurdle in developing AI-based treatments, particularly noting that cancer research benefits from vast pre-existing datasets. Establishing the needed infrastructure is vital for translating AI intelligence into effective…